<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1611211327
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GYNOCIN 10 IU/ml solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OXYTOCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01BB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gynocin contains a manufactured form of oxytocin (a natural hormone). It belongs to a group of medicines called oxytocics that make the muscles of the womb contract.</p><p>&nbsp;</p><p>Gynocin is used:</p><p>&bull;&nbsp;&nbsp;&nbsp; To start or help contractions during childbirth (labour)</p><p>&bull;&nbsp;&nbsp;&nbsp; To help in the management of a miscarriage</p><p>&bull;&nbsp;&nbsp;&nbsp; To prevent and control bleeding after delivery of your baby</p><p>&bull;&nbsp;&nbsp;&nbsp; During a caesarean section</p><p>&bull;&nbsp;&nbsp;&nbsp; Prevention and treatment of postpartum uterine atony and haemorrhage.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Gynocin:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; If you are allergic to oxytocin or any of the ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp; If your doctor thinks that to start or increase contractions of the womb would be unsuitable for you, for example:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Where contractions of the womb are unusually strong</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Where there are obstructions that may prevent delivery</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Where your baby may be short of oxygen</p><p>&bull;&nbsp;&nbsp;&nbsp; Where labour or vaginal delivery is not advisable, for example:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your baby&rsquo;s head is too large to fit through your pelvis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your baby is wrongly positioned in the birth canal</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the placenta lies near or over the neck of your womb</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your baby lacks oxygen due to blood vessels running across the neck of your womb</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the placenta separates from the womb before the baby is born</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there are one or more loops of umbilical cord between the baby and the neck of the womb, either before or after your waters break</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your womb is over-extended and more likely to tear, for example if you are carrying more than one baby or have too much water (amniotic fluid) in your womb</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had five or more pregnancies in the past or If your womb is scarred by previous caesarean section or other surgery</p><p>&bull;&nbsp;&nbsp; If you have been given medicines called prostaglandins (used to bring on labour or treat stomach ulcers). Gynocin should not be used for 6 hours after vaginal prostaglandins as the effects of both medicines may be increased.</p><p>&nbsp;</p><p>Gynocin should not be used for prolonged periods if:</p><p>&bull;&nbsp;&nbsp; Your contractions do not increase with the treatment</p><p>&bull;&nbsp;&nbsp; You have a condition known as severe pre-eclampsia (high blood pressure, protein in the urine and swelling)</p><p>&bull;&nbsp;&nbsp; You have severe problems with your heart or blood circulation.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p>Gynocin should only be administered by a healthcare professional in a hospital setting.</p><p>&nbsp;</p><p>Gynocin should not be given as rapid injection into a vein as this may cause low blood pressure, a sudden brief sensation of heat (often over the entire body), and an increased heart rate.</p><p>&nbsp;</p><p>Before you are given Gynocin tell your doctor if:</p><p>&bull;&nbsp;&nbsp;&nbsp; You are prone to chest pain due to pre-existing heart and/or circulation problems</p><p>&bull;&nbsp;&nbsp;&nbsp; You have a known irregular heart beat (&ldquo;long QT syndrome&rdquo;) or related symptoms, or are taking medicines known to cause the syndrome (see section &ldquo;Other medicines and Gynocin&rdquo;).</p><p>&bull;&nbsp;&nbsp;&nbsp; You have had a previous caesarean section</p><p>&bull;&nbsp;&nbsp;&nbsp; You are more than 35 years old</p><p>&bull;&nbsp;&nbsp;&nbsp; You have raised blood pressure or heart problems</p><p>&bull;&nbsp;&nbsp;&nbsp; Your womb was contracting strongly but has now begun to contract less strongly</p><p>&bull;&nbsp;&nbsp;&nbsp; You have been told by a doctor that normal delivery may be difficult for you due to the small size of your pelvis</p><p>&bull;&nbsp;&nbsp;&nbsp; You have kidney problems, as Gynocin can cause water retention</p><p>&bull;&nbsp;&nbsp;&nbsp; You have had complications during your pregnancy</p><p>&bull;&nbsp;&nbsp;&nbsp; You are more than 40 weeks pregnant.</p><p>&nbsp;</p><p>When Gynocin is given to induce and enhance labour, the infusion rate should be set to maintain a contraction pattern similar to normal labour and adjusted to individual response. Too high doses may cause very strong continuous contractions and possibly tearing of the womb, with serious complications for you and your baby.</p><p>Gynocin may rarely cause disseminated intravascular coagulation which causes symptoms including abnormal blood clotting, bleeding and anaemia.</p><p>&nbsp;</p><p>High doses of Gynocin may force amniotic fluid from your womb into your blood. This is known as amniotic fluid embolism.</p><p>&nbsp;</p><p>Large doses of Gynocin over a long period of time, whilst drinking or receiving large volumes of fluid may make your stomach feel very full, cause difficulty in breathing and lower salt levels in your blood.</p><p>&nbsp;</p><p>If any of the above applies to you, or if you are not sure, speak to your doctor before you receive Gynocin.</p><p>&nbsp;</p><p><strong>Latex allergy</strong></p><p>The active substance in Gynocin might cause a severe allergic reaction (anaphylaxis) in patients with latex allergy. Please tell your doctor if you know you are allergic to latex.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Gynocin</strong></p><p>Tell your doctor if you are taking or have recently taken any of the following medicines as they may interfere with Gynocin:</p><p>&bull;&nbsp;&nbsp;&nbsp; Prostaglandins (used to start labour or to treat stomach ulcers) and similar drugs as the effects of both drugs may be increased</p><p>&bull;&nbsp;&nbsp;&nbsp; Medicines that can cause an irregular heartbeat, as Gynocin may increase this effect</p><p>&bull;&nbsp;&nbsp;&nbsp; Anaesthetics which you breathe in (e.g. to put you to sleep during surgery, such as halothane, cyclopropane, sevoflurane or desflurane) as these may weaken your contractions, or cause problems with your heartbeat</p><p>&bull; Anaesthetic medicines for local or regional pain relief, in particular an epidural for pain relief during labour. Gynocin may increase the blood vessel narrowing effect of these medicines and cause an increase in blood pressure.</p><p>&nbsp;</p><p>Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>Gynocin with food and drink</strong></p><p>You may be told to keep the amount of fluids you drink to a minimum.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Based on wide experience of use and the nature of this medicine, it is not expected that oxytocin would be a risk to your baby when used correctly. Oxytocin may be found in small amounts in breast milk but is not expected to have harmful effects because it is quickly inactivated by your baby&rsquo;s digestive system.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Gynocin can start labour. Women with contractions should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will decide when and how to treat you with Gynocin. If you think that the effect of Gynocin is too strong or too weak, tell your doctor. While you are receiving Gynocin, both you and your baby will be closely monitored.</p><p>&nbsp;</p><p>Gynocin is usually diluted before use and given as an intravenous infusion (drip) into one of your veins.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>The usual dose is different in the following circumstances:</strong></p><p><em>To start or help contractions during labour</em></p><p>The rate of infusion will start at 2 to 8 drops per minute. This may be gradually increased to a maximum rate of 40 drops per minute. The infusion rate can often be reduced once the contractions reach an adequate level, about 3-4 contractions every 10 minutes.</p><p>&nbsp;</p><p>If your contractions do not reach the adequate level after 5 IU the attempt to start labour should be stopped and then repeated the following day.</p><p>&nbsp;</p><p><em>Miscarriage</em></p><p>The dose is 5 IU by infusion into a vein. In some cases this may be followed by a drip at 40 to 80 drops per minute.</p><p>&nbsp;</p><p><em>Caesarean section</em></p><p>The dose is 5 IU by infusion into a vein immediately after delivery of your baby.</p><p>&nbsp;</p><p><em>Prevention of bleeding after delivery</em></p><p>&bull;&nbsp;&nbsp;&nbsp; <em>Intravenous infusion (drip method)</em></p><p>The dose is 5 IU by infusion into a vein after delivery of the placenta.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; <em>Intramuscular</em> <em>administration</em></p><p>(1 ml) (10) units of oxytocin can be given after the delivery of the placenta.</p><p>&nbsp;</p><p><em>Treatment of bleeding after delivery</em></p><p>The dose is 5 IU by infusion into a vein. In some cases this may be followed by a drip containing 5 to 20 IU of oxytocin.</p><p>&nbsp;</p><p><em>Elderly (65 years and over)</em></p><p>There is no information on use in elderly patients. Oxytocin is not intended for use in the elderly.</p><p>&nbsp;</p><p><em>Children and adolescents</em></p><p>There is no information on use in children (2-11 years) or adolescents (12-17 years). Oxytocin is not intended for use in children or adolescents.</p><p>&nbsp;</p><p><em>Patients with kidney disease</em></p><p>There is no information on use in patients with kidney disease.</p><p>&nbsp;</p><p>However, you should tell your doctor if you suffer from kidney problems (see section 2 &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p><em>Patients with liver disease</em></p><p>There is no information on use in patients with liver disease.</p><p>&nbsp;</p><p><strong>If you are given more </strong><strong>Gynocin</strong><strong> than you should</strong></p><p>As this medicine is given to you in hospital, it is very unlikely that you will receive an overdose.</p><p>&nbsp;</p><p>If anyone accidentally receives this medicine, tell the hospital accident and emergency department or a doctor immediately. Show any left over medicines or the empty packet to the doctor.</p><p>&nbsp;</p><p><em>An overdose of Gynocin could cause:</em></p><p>&bull;&nbsp;&nbsp;&nbsp; Very strong contractions of your womb</p><p>&bull;&nbsp;&nbsp;&nbsp; Damage to your womb which could include tearing</p><p>&bull;&nbsp;&nbsp;&nbsp; The placenta to come away from your womb</p><p>&bull;&nbsp;&nbsp;&nbsp; Amniotic fluid (the fluid around the baby) to enter your bloodstream</p><p>&bull;&nbsp;&nbsp;&nbsp; Harm to your baby.</p><p>&nbsp;</p><p><strong>If you forget to take </strong><strong>Gynocin</strong><strong> </strong></p><p>As a doctor is giving you this medicine, you are unlikely to miss a dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, oxytocin can cause side effects, although not everyone gets them. Your doctor may consider it necessary to treat the side effects of oxytocin with other medicines.</p><p>&nbsp;</p><p><strong><em>Some side effects could be serious. </em></strong><strong><em>If any of the following occur, tell your doctor straight away:</em></strong></p><p><strong>The following side effect may affect between 1 and 10 in every 10,000 patients:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; A severe allergic (anaphylactic/anaphylactoid) reaction with difficulty in breathing, dizziness and lightheadedness, feeling faint, nausea, cold and clammy skin or a fast or weak pulse.</p><p>&bull;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue, throat, and/or extremities (possible signs of angioedema).</p><p>&nbsp;</p><p><strong><em>The following side effects have been reported in oxytocin.</em></strong></p><p><strong>Common side effects (more than 1 in 100 patients) of oxytocin include:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Feeling or being sick</p><p>&bull;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp; Fast or slow heartbeat</p><p>&nbsp;</p><p><strong>Uncommon side effects (more than 1 in 1,000 patients) of oxytocin include:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; An irregular heartbeat.</p><p>&nbsp;</p><p><strong>Rare side effects (more than 1 in 10,000 patients) of oxytocin include:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Skin rashes.</p><p><strong>&nbsp;</strong></p><p><strong><em>Other side effects</em></strong></p><p><strong>Effects in the mother:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Haemorrhage (bleeding)</p><p>&bull;&nbsp;&nbsp;&nbsp; Chest pain (angina)</p><p>&bull;&nbsp;&nbsp;&nbsp; Irregular heartbeat</p><p>&bull;&nbsp;&nbsp;&nbsp; Excessive or continuous contractions</p><p>&bull;&nbsp;&nbsp;&nbsp; Tearing of the womb</p><p>&bull;&nbsp;&nbsp;&nbsp; Fluid retention (water intoxication). Symptoms may include headache, anorexia (loss of appetite), feeling or being sick, stomach pain, sluggishness, drowsiness, unconsciousness, low levels of certain chemicals in the blood (e.g. sodium or potassium), fits.</p><p>&bull;&nbsp;&nbsp;&nbsp; Low blood salt levels</p><p>&bull;&nbsp;&nbsp;&nbsp; Sudden fluid overload in the lungs</p><p>&bull;&nbsp;&nbsp;&nbsp; Sudden brief sensation of heat often over the whole body</p><p>&bull;&nbsp;&nbsp;&nbsp; Abnormal clotting, bleeding and anaemia</p><p>&bull;&nbsp;&nbsp;&nbsp; Spasm of the muscles of the womb</p><p>&nbsp;</p><p><strong>Effects in the baby:</strong></p><p>Excessive contractions may cause low blood salt levels, shortage of oxygen, suffocation and death.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p><em>Before opening:</em></p><p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package.</p><p><em>After dilution: </em></p><p>The diluted solutions should be used immediately.</p><p>If your doctor decides to stop your treatment, return any unused medicine to the pharmacist. Only keep it if your doctor tells you to.</p><p>Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is oxytocin. &nbsp;</p><p>&nbsp;</p><p>Each 0.5 ml of Gynocin 5 IU/0.5 ml Concentrate for Solution for Injection/Infusion contains 5 IU oxytocin.</p><p>&nbsp;</p><p>Each 1 ml of Gynocin 10 IU/ml Concentrate for Solution for Injection/Infusion contains 10 IU oxytocin.</p><p>&nbsp;</p><p>The other ingredients are chlorobutanol, acetic acid and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gynocin 5 IU/0.5 ml and 10 IU/ml Concentrate for Solution for Injection/Infusion is a clear colorless sterile aqueous liquid in 1 ml clear glass type I ampoules.

Pack sizes: 
-	Gynocin 5 IU/0.5 ml Concentrate for Solution for Injection/Infusion: 6 Ampoules (0.5 ml). 
-	Gynocin 10 IU/ml Concentrate for Solution for Injection/Infusion: 6 Ampoules (1 ml).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder </strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer </strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 04/2021; version number SA3.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي جاينوسين على شكل مصنع من الأوكسيتوسين (هرمون طبيعي). وهو ينتمي إلى مجموعة من الأدوية اسمها معجلات الولادة التي تجعل عضلات الرحم تنقبض.</p><p>&nbsp;</p><p dir="RTL">يُستخدم جاينوسين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; لبدء تقلصات الرحم أو المساعدة في ذلك أثناء الولادة (المخاض)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; للمساعدة في السيطرة على حالات الإجهاض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; للوقاية من النزف والسيطرة عليه عقب الولادة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أثناء العمليات القيصرية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية والعلاج من وهن ونزف الرحم بعد الولادة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطائك جاينوسين:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من حساسية للأوكسيتوسين أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طبيبك يعتقد أن بدء تقلصات الرحم أو زيادتها لن يناسبك، على سبيل المثال:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت تقلصات الرحم أقوى من المعتاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت هناك عوائق قد تحول دون الولادة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان هناك احتمال أن يعاني الجنين من نقص الأكسجين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لا يُنصح بالمخاض أو الولادة المهبلية، على سبيل المثال:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان رأس الطفل أكبر من أن يمر خلال الحوض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان وضع الطفل في قناة الولادة خاطئًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت المشيمة موجودة بالقرب من عنق الرحم أو فوقه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانى الطفل من نقص الأكسجين بسبب الأوعية الدموية التي تمر عبر عنق الرحم لديكِ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انفصلت المشيمة عن الرحم قبل ولادة الطفل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان هناك حلقة أو أكثر في الحبل السري بين الطفل وعنق الرحم، سواء كان هذا قبل تدفق مياه المشيمة أو بعدها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تمدد الرحم لديك أكثر مما ينبغي لدرجة تجعله عرضة للتمزق، على سبيل المثال كما في حالة حملك في أكثر من طفل أو زيادة المياه (السائل السلوي) أكثر مما ينبغي في الرحم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تكرر حملك في السابق لخمس مرات أو أكثر أو تندب الرحم نتيجة عمليات قيصرية سابقة أو أي عملية جراحية أخرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا سبق وتم إعطائكِ أي من أدوية تسمى البروستاغلاندينات (تُستخدم لحث المخاض أو علاج قرح المعدة). لا يجب استخدام جاينوسين إلا بعد مرور 6 ساعات من البروستاغلاندينات المهبلية حتى لا يزداد أثر كل منهما.</p><p>&nbsp;</p><p dir="RTL">يجب ألا يُستخدم جاينوسين لفترات طويلة إذا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; لم تزيد التقلصات مع العلاج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; كنتَ تعانين من حالة تُسمى مقدمات الارتعاج الحاد (ارتفاع ضغط الدم، وجود بروتين في البول وتورم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; كنتَ تعانين من مشاكل شديدة في القلب أو الدورة الدموية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">يجب ألا يعطى جاينوسين إلا من متخصص الرعاية الصحية داخل المستشفى.</p><p>&nbsp;</p><p dir="RTL">يجب ألا يُعطى جاينوسين بالحقن السريع في الوريد لأن هذا قد يؤدي إلى انخفاض ضغط الدم، إحساس مفاجئ بالحرارة لوقت قصير (يعم هذا الجسم كله غالباً)، وزيادة في سرعة نبضات القلب.</p><p>&nbsp;</p><p dir="RTL">اخبري طبيبك قبل أن يتم إعطائك جاينوسين إذا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ عرضة لألم في الصدر نتيجة مشكلات موجودة من قبل في القلب و/أو الدورة الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ تعرفين أنكِ تعانين من عدم انتظام ضربات القلب (&quot;متلازمة طول فترة QT&quot;) أو أي من الأعراض المتعلقة بذلك، أو إذا كنتِ تتناولين الأدوية المعروفة بأنها تسبب هذه المتلازمة (انظر قسم &quot;الأدوية الأخرى وجاينوسين&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; سبق لكِ الخضوع لعملية قيصرية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; تجاوز عمركِ 35 سنة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ تعانين من ارتفاع ضغط الدم أو مشاكل في القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كان رحمك ينقبض بقوة ولكنه بدأ في الانقباض بقوة أقل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كان الطبيب قد أخبركِ أن الولادة الطبيعية ستكون صعبة في حالتك لصغر حجم الحوض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ تعانين من مشاكل بالكلى لأن جاينوسين قد يسبب احتباس سوائل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ سبق وعانيتِ من مضاعفات أثناء الحمل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كان الحمل قد مر عليه أكثر من 40 أسبوعاً.</p><p>&nbsp;</p><p dir="RTL">عند إعطاء جاينوسين لحث المخاض أو تعزيزه، يجب ضبط معدل التسريب بما يحافظ على نمط تقلصات يماثل المخاض الطبيعي مع التعديل بما يناسب الاستجابة الفردية لكل مريضة. قد تسبب الجرعات العالية أكثر من اللازم انقباضات قوية جداً ومتواصلة قد تؤدي بدورها إلى تمزق الرحم وحدوث مضاعفات خطيرة لكِ ولطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة، قد يسبب جاينوسين التخثر المنتثر داخل الأوعية والذي يسبب أعراض تتضمن جلطات دموية غير طبيعية، النزف وفقر الدم.</p><p>&nbsp;</p><p dir="RTL">قد تدفع الجرعات العالية من جاينوسين السائل السلوي من رحم إلى الدم لديكِ. ويُعرف هذا باسم الانصمام بالسائل السلوي.</p><p>&nbsp;</p><p dir="RTL">الجرعات الكبيرة من جاينوسين على مدار مدة طويلة، مع شرب المياه أو الحصول على كميات كبيرة من السوائل قد تجعلك تشعرين بامتلاء معدتك، تسبب صعوبة في التنفس وتخفض مستوى الأملاح في الدم.</p><p>&nbsp;</p><p dir="RTL">إذا كان ينطبق عليكِ أي من المذكور أعلاه، أو إذا لم تكوني متأكدة، تحدثي مع طبيبك قبل أن تتلقي جاينوسين.</p><p>&nbsp;</p><p dir="RTL"><strong>الحساسية تجاه اللاتكس</strong></p><p dir="RTL">قد تسبب المادة الفعالة في جاينوسين رد فعل تحسسي شديد (تَأَقّ) عند المرضى الذين يعانون من حساسية تجاه اللاتكس. يرجى إخبار طبيبكِ إذا كنت تعرفين أنك تعانين من حساسية تجاه اللاتكس.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وجاينوسين</strong></p><p dir="RTL">اخبري طبيبك أو الصيدلي إذا كنتِ تأخذين، أخذتِ مؤخراً، أو قد تأخذين أيًا من الأدوية التالية لأنها قد تتعارض مع جاينوسين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مجموعة البروستاغلاندينات (تُستخدم لبدء المخاض أو علاج قرح المعدة) وغيره من الأدوية المشابهة لأن هذا يزيد من أثر كليهما</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تسبب عدم انتظام ضربات القلب لأن جاينوسين قد يزيد من هذا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أدوية التخدير التي تؤخذ بالاستنشاق (على سبيل المثال التي تُستخدم لتنويمك أثناء الجراحة، مثل الهالوثان أو السكلوبروبان أو السيفوفلوران أو الديسفلوران)، لأن هذه الأدوية قد تضعف الانقباضات أو تسبب مشكلات في ضربات القلب</p><p dir="RTL">&bull; أدوية التخدير التي تُستخدم لتسكين الألم في موضع أو في منطقة، وخاصة الأدوية التي تُحقن فوق الجافية لتخفيف الألم أثناء المخاض. قد يزيد جاينوسين من تضييق هذه الأدوية للأوعية الدموية مما قد يؤدي إلى ارتفاع ضغط الدم.</p><p>&nbsp;</p><p dir="RTL">أخبري الطبيب إذا كنتِ تتناولين حاليًا، أو تناولتِ مؤخرًا، أي أدوية بما في ذلك الأدوية التي تُصرف دون وصفة طبية.</p><p>&nbsp;</p><p dir="RTL"><strong>جاينوسين مع الطعام والشراب</strong></p><p dir="RTL">قد يُطلب منكِ تقليل كمية السوائل التي تشربينها إلى الحد الأدنى.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">في ضوء التجارب الكثيرة مع استخدام هذا الدواء وطبيعته، لا يُتوقع أن يمثل أوكسيتوسين أي خطورة على طفلك عند استعماله استعمالاً صحيحاً. قد يُفرز أوكسيتوسين بكميات ضئيلة في لبن الثدي إلا أنه ليس من المتوقع أن يكون له أي آثار ضارة لأن الجهاز الهضمي للرضيع يقضي على مفعوله بسرعة.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يؤدي جاينوسين إلى بدء المخاض. النساء اللاتي بدأت لديهن الانقباضات يجب ألا يقدن السيارات أو يستخدمن الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقرر طبيبك متى يعالجك باستخدام جاينوسين وأسلوب العلاج. إذا كنتِ تشعرين أن تأثير هذا الدواء قوي جداً أو ضعيف جداً، فأخبري طبيبك. أثناء تلقيكِ جاينوسين، ستخضعين أنتِ وجنينك لمتابعة دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخفف جاينوسين عادة قبل الاستخدام ويُعطى بالتسريب (التنقيط) الوريدي في أحد الأوردة لديكِ.</p><p><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>تختلف الجرعة المعتادة في كل حالة من الحالات التالية:</strong></p><p dir="RTL"><em>لبدء تقلصات الرحم أو المساعدة على ذلك أثناء المخاض</em></p><p dir="RTL">سيبدأ التسريب بمعدل قطرتين إلى 8 قطرات في الدقيقة. ويمكن زيادة هذا تدريجياً ليصل إلى الحد الأقصى الذي يبلغ 40 قطرة في الدقيقة. وفي أغلب الأحوال يمكن تقليل معدل التسريب بمجرد وصول الانقباضات إلى مستوى كافٍ، أي ما يقرب من 3-4 انقباضات كل 10 دقائق.</p><p>&nbsp;</p><p dir="RTL">وإذا لم تصل الانقباضات لديكِ إلى المستوى الكافي بعد 5 وحدة دولية، فيجب إيقاف محاولات حث الجسم على بدء المخاض وتكرارها في اليوم التالي.</p><p>&nbsp;</p><p dir="RTL"><em>الإجهاض</em></p><p dir="RTL">تبلغ الجرعة 5 وحدات دولية عن طريق التسريب في الوريد. في بعض الحالات تُتبع هذه الجرعة بتسريب وريدي بمعدل 40 إلى 80 قطرة في الدقيقة.</p><p>&nbsp;</p><p dir="RTL"><em>العمليات القيصرية</em></p><p dir="RTL">تبلغ الجرعة 5 وحدات دولية عن طريق التسريب في الوريد عقب الولادة مباشرة.</p><p>&nbsp;</p><p dir="RTL"><em>الوقاية من النزف بعد الولادة</em></p><p dir="RTL"><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>التسريب الوريدي (طريقة التقطير)</em></p><p dir="RTL">تبلغ الجرعة 5 وحدات دولية عن طريق التسريب في الوريد عقب خروج المشيمة.</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; <em>الاستعمال</em> <em>في العضل</em></p><p dir="RTL">عقب خروج المشيمة، يمكن إعطاء (1 مللتر) (10) وحدات من الأوكسيتوسين.</p><p>&nbsp;</p><p dir="RTL"><em>علاج النزف عقب الولادة</em></p><p dir="RTL">تبلغ الجرعة 5 وحدات دولية عن طريق التسريب في الوريد. في بعض الحالات تُتبع هذه الجرعة بتسريب وريدي يحتوي على 5 وحدات إلى 20 وحدة دولية من الأوكسيتوسين.</p><p>&nbsp;</p><p dir="RTL"><em>كبار السن (65 عاماً أو أكبر)</em></p><p dir="RTL">لا تتوفر معلومات عن الاستخدام في كبار السن، إلا أن أوكسيتوسين لا يُوصف للاستخدام في كبار السن.</p><p>&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقين</em></p><p dir="RTL">لا تتوفر معلومات عن الاستخدام مع الأطفال (2-11 عاماً) أو المراهقين (12-17 عاماً). لا يُوصف الأوكسيتوسين للاستخدام في الأطفال أو المراهقين.</p><p>&nbsp;</p><p dir="RTL"><em>المريضات اللاتي يعانين من مرض في الكلى</em></p><p dir="RTL">لا تتوفر معلومات عن الاستخدام مع المريضات اللاتي تعانين من مرض في الكلى.</p><p>&nbsp;</p><p dir="RTL">مع ذلك، ينبغي عليكِ أن تخبري طبيبك إذا كنتِ تعانين من مشاكل في الكلى (انظري القسم 2 &quot;الاحتياطات والتحذيرات&quot;).</p><p>&nbsp;</p><p dir="RTL"><em>المريضات اللاتي يعانين من مرض في الكبد</em></p><p dir="RTL">لا تتوفر معلومات عن الاستخدام مع المريضات اللاتي تعانين من مرض في الكبد.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك </strong><strong>جاينوسين أكثر من اللازم</strong></p><p dir="RTL">بما أن هذا الدواء سيُعطى لكِ في المستشفى، فليس من المتوقع أبداً أن تتلقي جرعة زائدة.</p><p>&nbsp;</p><p dir="RTL">إذا تلقى أي شخص على هذا الدواء بطريق الخطأ، فاتصلي بقسم الحوادث والطوارئ بالمستشفى أو طبيب فوراً. قدمّي الأدوية المتبقية أو العبوة الفارغة للطبيب.</p><p>&nbsp;</p><p dir="RTL"><em>قد تسبب الجرعة الزائدة من جاينوسين ما يلي:</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; انقباضات قوية جداً بالرحم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; تلف بالرحم قد يصل إلى التمزق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; خروج المشيمة من الرحم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; دخول السائل السلوي (السائل المحيط بالجنين) إلى مجرى الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الإضرار بجنينك.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيتِ أخذ </strong><strong>جاينوسين</strong><strong> </strong></p><p dir="RTL">بما أن الطبيب هو الذي يتولى إعطاءك الدواء، فإنه لا يُحتمل أن تفوتك الجرعة.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، اسألي طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب الأوكسيتوسين آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لكل من يأخذه. قد يرى الطبيب ضرورة علاج الآثار الجانبية للأوكسيتوسين باستخدام أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong><em>بعض الآثار الجانبية قد تكون خطيرة. </em></strong><strong><em>اخبري طبيبك على الفور إذا ظهرت عليك أي من الأعراض التالية:</em></strong></p><p dir="RTL"><strong>قد تؤثر الآثار الجانبية التالية بين 1 و10 من كل 10000 مريضة:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي (تأق/ تأقاني) مصحوب بصعوبة في التنفس، دوخة ودوار، شعور بالإغماء، غثيان، جلد بارد ومتندٍ بالعرق أو سرعة أو بطء النبض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين، اللسان، الحلق و/أو الأطراف (علامات محتملة للوذمة الوعائية)</p><p>&nbsp;</p><p dir="RTL"><strong><em>تم الإبلاغ عن حدوث الآثار الجانبية التالية عند أخذ </em></strong><strong><em>أوكسيتوسين.</em></strong></p><p dir="RTL"><strong>تشمل الآثار الجانبية الشائعة (أكثر من 1 من كل 100 مريضة) للأوكسيتوسين:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان أو القيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; بطء أو سرعة في ضربات القلب</p><p>&nbsp;</p><p dir="RTL"><strong>تشمل الآثار الجانبية غير الشائعة (أكثر من 1 من كل 1000 مريضة) للأوكسيتوسين:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب</p><p>&nbsp;</p><p dir="RTL"><strong>تشمل الآثار الجانبية النادرة (أكثر من 1 من كل 10000 مريضة) للأوكسيتوسين:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>آثار جانبية أخرى</em></strong></p><p dir="RTL"><strong>الآثار على الأم:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; النزف (نزف دموي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر (ذبحة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; انقباضات زائدة أو متواصلة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; تمزق الرحم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; احتباس سوائل (التسمم بالماء). قد تشمل الأعراض الصداع، القهم (فقدان الشهية)، الشعور بالغثيان أو القيء، ألم بالمعدة، الخمول، النعاس، فقدان الوعي، انخفاض مستوى بعض المواد الكيماوية في الدم (على سبيل المثال الصوديوم أو البوتاسيوم)، نوبات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات أملاح الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; السوائل الزائدة المفاجئة في الرئتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; إحساس مفاجئ بالحرارة لوقت قصيرة غالبًا ما يعم الجسم كله</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; حالات غير طبيعية من التخثر، النزف وفقر الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; تشنج عضلات الرحم</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار على الطفل:</strong></p><p dir="RTL">قد تؤدي الانقباضات الزائدة إلى انخفاض مستوى أملاح الدم، نقص في الأكسجين، الاختناق والوفاة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL"><em>قبل الفتح:</em></p><p dir="RTL">يحفظ داخل الثلاجة (2-8˚ مئوية).</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL"><em>بعد التخفيف: </em></p><p dir="RTL">يجب استخدام المحاليل المخففة فوراً.<sup> </sup></p><p dir="RTL">إذا قرر طبيبكِ إيقاف علاجكِ، فعليكِ إرجاع أي دواء غير مستخدم إلى الصيدلي. يمكنكِ الاحتفاظ به فقط إذا أخبركِ طبيبك بذلك.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أوكسيتوسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل 0.5 مللتر من جاينوسين 5 وحدات دولية/0.5 مللتر مركز للتخفيف قبل الحقن/التسريب على 5 وحدات دولية أوكسيتوسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل 1 مللتر من جاينوسين 10 وحدات دولية/مللتر مركز للتخفيف قبل الحقن/التسريب على 10 وحدات دولية أوكسيتوسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي كلوروبيوتانول، حمض الأسيتيك وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">جاينوسين 5 وحدات دولية/0.5 مللتر و10 وحدات دولية/مللتر مركز للتخفيف قبل الحقن/التسريب هو سائل مائي صافٍ عديم اللون معقّم في أمبولات زجاجية شفافة بسعة 1 مللتر من النوع &nbsp;رقم واحد.</p><p style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">حجم العبوات:</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp; جاينوسين 5 وحدات دولية/0.5 مللتر مركز للتخفيف قبل الحقن/التسريب: 6 أمبولات (0,5 مللتر).</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp; جاينوسين 10 وحدات دولية/مللتر مركز للتخفيف قبل الحقن/التسريب: 6 أمبولات (1مللتر).</p><p style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>اسم وعنوان مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم &deg;8, 8A e 8B، فارفانسا<br />2705-906 تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul><li dir="RTL">&nbsp; &nbsp; المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul><li dir="RTL">&nbsp; &nbsp; دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2021/04، رقم النسخة SA3.1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gynocin 10 IU/ml Concentrate for Solution for Injection/Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 1 ml contains 10 IU oxytocin. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for injection/infusion.

Clear colorless sterile aqueous liquid. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Antepartum</em></p><ul><li>Induction of labour for medical reasons, e.g. in cases of Rh problems, post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia)</li><li>Stimulation of labour in hypotonic uterine inertia</li><li>Early stages of pregnancy as adjunctive therapy for the management of incomplete, inevitable, or missed abortion.</li></ul><p>&nbsp;</p><p><em>Postpartum</em></p><ul><li>During caesarean section, but following delivery of the child</li><li>Prevention and treatment of postpartum uterine atony and haemorrhage.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Method of administration for each indication:</strong></p><p style="text-align:justify"><em>Induction or enhancement of labour</em></p><p style="text-align:justify">Oxytocin should not be started for 6 hours following administration of vaginal prostaglandins. Gynocin should be administered as an i.v. drip infusion or, preferably, by means of a variable-speed infusion pump. For drip infusion it is recommended that 5 IU of Gynocin be added to 500 ml of a physiological electrolyte solution (such as sodium chloride 0.9%). For patients in whom infusion of sodium chloride must be avoided, 5% dextrose solution may be used as the diluent (see Section 4.4 &ldquo;Special warnings and precautions for use&rdquo;). To ensure even mixing, the bottle or bag must be turned upside down several times before use.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The initial infusion rate should be set at 1 to 4 milliunits/minute (2 to 8 drops/minute). It may be gradually increased at intervals not shorter than 20 minutes and increments of not more than 1-2 milliunits/minute, until a contraction pattern similar to that of normal labour is established. In pregnancy near term this can often be achieved with an infusion of less than 10 milliunits/minute (20 drops/minute), and the recommended maximum rate is 20 milliunits/minute (40 drops/minute). In the unusual event that higher rates are required, as may occur in the management of foetal death in utero or for induction of labour at an earlier stage of pregnancy, when the uterus is less sensitive to oxytocin, it is advisable to use a more concentrated Gynocin solution, e.g., 10 IU in 500 ml.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">When using a motor-driven infusion pump which delivers smaller volumes than those given by drip infusion, the concentration suitable for infusion within the recommended dosage range must be calculated according to the specifications of the pump.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The frequency, strength and duration of contractions as well as the foetal heart rate must be carefully monitored throughout the infusion. Once an adequate level of uterine activity is attained, aiming for 3 to 4 contractions every 10 minutes, the infusion rate can often be reduced. In the event of uterine hyperactivity and/or foetal distress, the infusion must be discontinued immediately.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">If, in women who are at term or near term, regular contractions are not established after the infusion of a total amount of 5 IU, it is recommended that the attempt to induce labour be ceased; it may be repeated on the following day, starting again from a rate of 1 to 4 milliunits/minute (see Section 4.3 &ldquo;Contraindications&rdquo;).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In women given Gynocin for induction or enhancement of labour, the infusion should be continued at an increased rate during the third stage of labour and for the next few hours thereafter.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Method of administration for each indication, continued:</strong></p><p style="text-align:justify"><em>Incomplete, inevitable or missed abortion</em></p><p style="text-align:justify">5 IU by i.v. infusion (5 IU diluted in physiological electrolyte solution and administered as an i.v. drip infusion or preferably, by means of a variable-speed infusion pump over 5 minutes), if necessary followed by i.v. infusion at a rate of 20 to 40 milliunits/minute.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><em>Caesarean section</em></p><p style="text-align:justify">5 IU by i.v. infusion (5 IU diluted in physiological electrolyte solution and administered as an i.v. drip infusion or, preferably, by means of a variable-speed infusion pump over 5 minutes) immediately after delivery.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Prevention of postpartum uterine haemorrhage</em></p><ul><li style="text-align:justify">&nbsp; &nbsp;&nbsp;<em>Intravenous infusion (drip method)</em></li></ul><p style="text-align:justify">The usual dose is 5 IU by i.v. infusion (5 IU diluted in physiological electrolyte solution and administered as an i.v. drip infusion or, preferably, by means of a variable-speed infusion pump over 5 minutes) after delivery of the placenta.</p><p style="text-align:justify">&nbsp;</p><ul><li style="text-align:justify">&nbsp; &nbsp;&nbsp;<em>Intramuscular</em> <em>administration</em></li></ul><p style="text-align:justify">(1 ml) (10) units of oxytocin can be given after the delivery of the placenta.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><em>Treatment of postpartum uterine haemorrhage</em></p><p style="text-align:justify">5 IU by i.v. infusion (5 IU diluted in physiological electrolyte solution and administered as an i.v. drip infusion or, preferably, by means of a variable-speed infusion pump over 5 minutes), followed in severe cases by i.v. infusion of a solution containing 5 to 20 IU of oxytocin in 500 ml of an electrolyte containing diluent, run at the rate necessary to control uterine atony.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Route of administration:</strong></p><p style="text-align:justify">Intravenous infusion or Intramuscular injection.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Special populations</strong></p><p style="text-align:justify"><em>Renal impairment</em></p><p style="text-align:justify">No studies have been performed in renally impaired patients.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Hepatic impairment</em></p><p style="text-align:justify">No studies have been performed in hepatically impaired patients.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Paediatric population</em></p><p style="text-align:justify">No studies have been performed in paediatric patients.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Elderly population</em></p><p style="text-align:justify">No studies have been performed in elderly patients (65 years old and over).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
•	Hypertonic uterine contractions, mechanical obstruction to delivery, foetal distress.

Any condition in which, for foetal or maternal reasons, spontaneous labour is inadvisable and/or vaginal delivery is contra-indicated: e.g.:
•	Significant cephalopelvic disproportion
•	Foetal malpresentation
•	Placenta praevia and vasa praevia
•	Placental abruption
•	Cord presentation or prolapse
•	Overdistension or impaired resistance of the uterus to rupture as in multiple pregnancy
•	Polyhydramnios
•	Grand multiparity
•	In the presence of a uterine scar resulting from major surgery including classical caesarean section.

Gynocin should not be used for prolonged periods in patients with oxytocin-resistant uterine inertia, severe pre-eclamptic toxaemia or severe cardiovascular disorders.

Gynocin must not be administered within 6 hours after vaginal prostaglandins have been given (see section 4.5 Interaction with other medicinal products and other forms of interaction).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Oxytocin must only be administered as an i.v. infusion and never by i.v. bolus injection as it may cause an acute short-lasting hypotension accompanied with flushing and reflex tachycardia.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Induction of labour</em></p><p style="text-align:justify">The induction of labour by means of Gynocin should be attempted only when strictly indicated for medical reasons. Administration should only be under hospital conditions and qualified medical supervision.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Cardiovascular disorders</em></p><p style="text-align:justify">Gynocin should be used with caution in patients who have a pre-disposition to myocardial ischaemia due to pre-existing cardiovascular disease (such as hypertrophic cardiomyopathy, valvular heart disease and/or ischaemic heart disease including coronary artery vasospasm), to avoid significant changes in blood pressure and heart rate in these patients.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>QT syndrome</em></p><p style="text-align:justify">Gynocin should be given with caution to patients with known &#39;long QT syndrome&#39; or related symptoms and to patients taking drugs that are known to prolong the QTc interval (see section 4.5 Interaction with other medicinal products and other forms of interaction).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">When oxytocin is given for induction and enhancement of labour:</p><ul><li style="text-align:justify">Foetal distress and foetal death: Administration of oxytocin at excessive doses results in uterine overstimulation which may cause foetal distress, asphyxia and death, or may lead to hypertonicity, tetanic contractions or rupture of the uterus. Careful monitoring of foetal heart rate and uterine motility (frequency, strength, and duration of contractions) is essential, so that the dosage may be adjusted to individual response.</li><li style="text-align:justify">Particular caution is required in the presence of borderline cephalopelvic disproportion, secondary uterine inertia, mild or moderate degrees of pregnancy-induced hypertension or cardiac disease, and in patients above 35 years of age or with a history of lower-uterine-segment caesarean section.</li><li style="text-align:justify">Disseminated intravascular coagulation: In rare circumstances, the pharmacological induction of labour using uterotonic agents, including oxytocin increases the risk of post partum disseminated intravascular coagulation (DIC). The pharmacological induction itself and not a particular agent is linked to such risk. This risk is increased in particular if the woman has additional risk factors for DIC such as being 35 years of age or over, complications during pregnancy and gestational age more than 40 weeks. In these women, oxytocin or any other alternative drug should be used with care, and the practitioner should be alerted by signs of DIC.</li></ul><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Intrauterine death</em></p><p style="text-align:justify">In the case of foetal death&nbsp;<em>in utero</em>, and/or in the presence of meconium-stained amniotic fluid, tumultuous labour must be avoided, as it may cause amniotic fluid embolism.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Water intoxication</em></p><p style="text-align:justify">Because oxytocin possesses slight antidiuretic activity, its prolonged i.v. administration at high doses in conjunction with large volumes of fluid, as may be the case in the treatment of inevitable or missed abortion or in the management of postpartum haemorrhage, may cause water intoxication associated with hyponatraemia. The combined antidiuretic effect of oxytocin and the i.v. fluid administration may cause fluid overload leading to a haemodynamic form of acute pulmonary oedema without hyponatraemia. To avoid these rare complications, the following precautions must be observed whenever high doses of oxytocin are administered over a long time: an electrolyte-containing diluent must be used (not dextrose); the volume of infused fluid should be kept low (by infusing oxytocin at a higher concentration than recommended for the induction or enhancement of labour at term); fluid intake by mouth must be restricted; a fluid balance chart should be kept, and serum electrolytes should be measured when electrolyte imbalance is suspected.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Renal Impairment</em></p><p style="text-align:justify">Caution should be exercised in patients with severe renal impairment because of possible water retention and possible accumulation of oxytocin (see section 5.2 Pharmacokinetics).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Anaphylaxis in women with latex allergy</em></p><p style="text-align:justify">There have been reports of anaphylaxis following administration of oxytocin in women with a known latex allergy. Due to the existing structural homology between oxytocin and latex, latex allergy/intolerance may be an important predisposing risk factor for anaphylaxis following oxytocin administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Interaction resulting in a concomitant use not recommended.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Prostaglandins and their analogues</em></p><p style="text-align:justify">Prostaglandins and its analogues facilitate contraction of the myometrium hence oxytocin can potentiate the uterine action of prostaglandins and analogues and vice versa (see section 4.3 Contraindications).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Drugs prolonging the QT interval</em></p><p style="text-align:justify">Oxytocin should be considered as potentially arrhythmogenic, particularly in patients with other risk factors for Torsades de Pointes such as drugs which prolong the QT interval or in patients with history of long QT syndrome (see section 4.4 Special warnings and precautions for use).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Interactions to be considered</strong></p><p style="text-align:justify"><em>Inhalation anaesthetics</em></p><p style="text-align:justify">Inhalation anaesthetics (e.g. cyclopropane, halothane, sevoflurane, desflurane) have a relaxing effect on the uterus and produce a notable inhibition of uterine tone and thereby, may diminish the uterotonic effect of oxytocin. Their concurrent use with oxytocin has also been reported to cause cardiac rhythm disturbances.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Vasoconstrictors/Sympathomimetics</em></p><p style="text-align:justify">Oxytocin may enhance the vasopressor effects of vasoconstrictors and sympathomimetics, even those contained in local anaesthetics.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Caudal anaesthetics</em></p><p style="text-align:justify">When given during or after caudal block anaesthesia, oxytocin may potentiate the pressor effect of sympathomimetic vasoconstrictor agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Pregnancy</em></p><p style="text-align:justify">Based on the wide experience with this drug and its chemical structure and pharmacological properties, it is not expected to present a risk of foetal abnormalities when used as indicated.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">One study has shown that treatment of rats with oxytocin in early pregnancy at doses considered sufficiently in excess of the maximum recommended human dose caused embryonic loss. No standard reproductive performance studies with oxytocin are available.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Lactation</em></p><p style="text-align:justify">Oxytocin may be found in small quantities in mother&#39;s breast milk. However, oxytocin is not expected to cause harmful effects in the newborn because it passes into the alimentary tract where it undergoes rapid inactivation.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Females and males of reproductive potential</em></p><p style="text-align:justify">Not applicable for oxytocin because of the targeted indications.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Infertility</em></p><p style="text-align:justify">Not applicable for oxytocin because of the targeted indications.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Gynocin can induce labour, therefore caution should be exercised when driving or operating machines. Women with uterine contractions should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">As there is a wide variation in uterine sensitivity, uterine spasm may be caused in some instances by what are normally considered to be low doses. When oxytocin is used by i.v. infusion for the induction or enhancement of labour, administration at too high doses results in uterine overstimulation which may cause foetal distress, asphyxia, and death, or may lead to hypertonicity, tetanic contractions, soft tissue damage or rupture of the uterus.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Rapid i.v. bolus injection of oxytocin at doses amounting to several IU may result in acute short-lasting hypotension accompanied with flushing and reflex tachycardia (see section 4.4 Special warnings and precautions for use). These rapid haemodynamic changes may result in myocardial ischaemia, particularly in patients with pre-existing cardiovascular disease. Rapid i.v. bolus injection of oxytocin at doses amounting to several IU may also lead to QTc prolongation.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In rare circumstances the pharmacological induction of labour using uterotonic agents, including oxytocin, increases the risk of postpartum disseminated intravascular coagulation (see section 4.4 Special warnings and precautions for use).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Water intoxication</em></p><p style="text-align:justify">Water intoxication associated with maternal and neonatal hyponatraemia has been reported in cases where high doses of oxytocin together with large amounts of electrolyte-free fluid have been administered over a prolonged period of time (see Section 4.4 &ldquo;Special warnings and precautions for use&rdquo;). The combined antidiuretic effect of oxytocin and the i.v. fluid administration may cause fluid overload leading to a haemodynamic form of acute pulmonary oedema without hyponatraemia (see section 4.4. Special warnings and precautions for use).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Symptoms of water intoxication include:</p><p style="text-align:justify">1.&nbsp; Headache, anorexia, nausea, vomiting and abdominal pain.</p><p style="text-align:justify">2.&nbsp; Lethargy, drowsiness, unconsciousness and grand-mal type seizures.</p><p style="text-align:justify">3.&nbsp; Low blood electrolyte concentration.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Undesirable effects (Tables 1 and 2) are ranked under heading of frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100, &lt; 1/10); uncommon (&ge; 1/1,000, &lt; 1/100); rare (&ge; 1/10,000, &lt; 1/1,000); very rare (&lt; 1/10,000), including isolated reports; not known (cannot be estimated from the available data).The ADRs tabulated below are based on clinical trial results as well as postmarketing reports.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The adverse drug reactions derived from post-marketing experience with oxytocin are via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Table 1:</strong> Adverse drug reactions in mother</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>System organ class</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Adverse drug reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Immune system disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Rare: Anaphylactic/Anaphylactoid reaction associated with dyspnoea, hypotension or Anaphylactic/Anaphylactoid shock</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Nervous system disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Common: Headache</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Cardiac disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Common Tachycardia, bradycardia</p><p style="text-align:justify">Uncommon: Arrhythmia</p><p style="text-align:justify">Not known: Myocardial ischaemia,</p><p style="text-align:justify">Electrocardiogram QTc prolongation</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Vascular disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Not known: Hypotension, haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Gastrointestinal disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Common: Nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Rare: Rash</p><p style="text-align:justify">Not Known: Angioedema</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Pregnancy, puerperium and perinatal conditions</p></td><td style="vertical-align:top"><p style="text-align:justify">Not known: Uterine hypertonus, tetanic contractions of uterus, rupture of the uterus</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Not known: Water intoxication, maternal hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Not known: Acute pulmonary oedema</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">General disorders and administration site conditions</p></td><td style="vertical-align:top"><p style="text-align:justify">Not known: Flushing</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Not known: Disseminated intravascular coagulation</p></td></tr></tbody></table><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Table 2:</strong> Adverse drug reactions in foetus/neonate</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>System organ class</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Adverse drug reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Pregnancy, puerperium and perinatal conditions</p></td><td style="vertical-align:top"><p style="text-align:justify">Not known: Foetal distress syndrome, asphyxia and death</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p style="text-align:justify">Not known: Neonatal hyponatraemia</p></td></tr></tbody></table><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Reporting of suspected adverse reactions</u></p><p style="text-align:justify">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li style="text-align:justify">&nbsp; &nbsp; Saudi Arabia</li></ul><p style="text-align:justify">The National Pharmacovigilance Centre (NPC)</p><p style="text-align:justify">SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:justify">Website: https://ade.sfda.gov.sa</p><p style="text-align:justify">&nbsp;</p><ul><li style="text-align:justify">&nbsp; &nbsp; Other GCC States</li></ul><p style="text-align:justify">Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">The fatal dose of oxytocin has not been established. Oxytocin is subject to inactivation by proteolytic enzymes of the alimentary tract. Hence it is not absorbed from the intestine and is not likely to have toxic effects when ingested.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The symptoms and consequences of overdosage are those mentioned under sections 4.4 &ldquo;Special warnings and precautions for use&rdquo; and 4.8 &ldquo;Undesirable effects&rdquo;. In addition, as a result of uterine overstimulation, placental abruption and/or amniotic fluid embolism have been reported.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Treatment:</em>&nbsp;When signs or symptoms of overdosage occur during continuous i.v. administration of oxytocin, the infusion must be discontinued at once and oxygen should be given to the mother. In cases of water intoxication it is essential to restrict fluid intake, promote diuresis, correct electrolyte imbalance, and control convulsions that may eventually occur. In the case of coma, a free airway should be maintained with routine measures normally employed in the nursing of the unconscious patient.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: Posterior pituitary lobe hormones</p><p style="text-align:justify">ATC code: H01B B02</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Mechanism of action</em></p><p style="text-align:justify">Oxytocin is a cyclic nonapeptide that is obtained by chemical synthesis. This synthetic form is identical to the natural hormone that is stored in the posterior pituitary and released into the systemic circulation in response to suckling and labour.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Oxytocin stimulates the smooth muscle of the uterus, more powerfully towards the end of pregnancy, during labour, and immediately postpartum. At these times, the oxytocin receptors in the myometrium are increased.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The oxytocin receptors are G-proteins coupled receptors. Activation of receptor by oxytocin triggers release of calcium from intracellular stores and thus leads to myometrial contraction.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Oxytocin elicits rhythmic contractions in upper segment of uterus, similar in frequency, force and duration to those observed during labour.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Being synthetic, oxytocin does not contain vasopressin, but even in its pure form oxytocin possesses some weak intrinsic vasopressin-like antidiuretic activity.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Based on in vitro studies, prolonged exposure of oxytocin had been reported to cause desensitisation of oxytocin receptors probably due to down-regulation of oxytocin-binding sites, destabilisation of oxytocin receptors mRNA and internalisation of oxytocin receptors.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Plasma levels and onset/duration of effect</em></p><p style="text-align:justify">Intravenous infusion. When oxytocin is given by continuous i.v. infusion at doses appropriate for induction or enhancement of labour, the uterine response sets in gradually and usually reaches a steady state within 20 to 40 minutes. The corresponding plasma levels of oxytocin are comparable to those measured during spontaneous first-stage labour. For example, oxytocin plasma levels in 10 pregnant women at term receiving a 4 milliunits per minute intravenous infusion were 2 to 5 microunits/ml. Upon discontinuation of the infusion, or following a substantial reduction in the infusion rate, e.g. in the event of overstimulation, uterine activity declines rapidly but may continue at an adequate lower level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Absorption</em></p><p style="text-align:justify">Plasma levels of oxytocin following intravenous infusion at 4 milliunits per minute in pregnant women at term were 2 to 5 microunits/ml.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Distribution</em></p><p style="text-align:justify">The steady-state volume of distribution determined in 6 healthy men after i.v. injection is 12.2 L or 0.17 L/kg. Plasma protein binding is negligible for oxytocin. It crosses the placenta in both directions. Oxytocin may be found in small quantities in mother&#39;s breast milk.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Biotransformation/Metabolism</em></p><p style="text-align:justify">Oxytocinase is a glycoprotein aminopeptidase that is produced during pregnancy and appears in the plasma. It is capable of degrading oxytocin. It is produced from both the mother and the foetus. Liver and kidney plays a major role in metabolising and clearing oxytocin from the plasma. Thus, liver, kidney and systemic circulation contribute to the biotransformation of oxytocin.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Elimination</em></p><p style="text-align:justify">Plasma half-life of oxytocin ranges from 3 to 20 min. The metabolites are excreted in urine whereas less than 1% of the oxytocin is excreted unchanged in urine. The metabolic clearance rate amounts to 20 ml/kg/ min in the pregnant woman.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Renal impairment</em></p><p style="text-align:justify">No studies have been performed in renally impaired patients. However, considering the excretion of oxytocin and its reduced urinary excretion because of anti-diuretic properties, the possible accumulation of oxytocin can result in prolonged action.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Hepatic impairment</em></p><p style="text-align:justify">No studies have been performed in hepatically impaired patients. Pharmacokinetic alteration in patients with impaired hepatic function is unlikely since metabolising enzyme, oxytocinase, is not confined to liver alone and the oxytocinase levels in placenta during the term has significantly increased. Therefore, biotransformation of oxytocin in impaired hepatic function may not result in substantial changes in metabolic clearance of oxytocin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pre-clinical data for oxytocin reveal no special hazard for humans based on conventional studies of single dose acute toxicity, genotoxicity, and mutagenicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Chlorobutanol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Acetic acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Water for injection</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Oxytocin should not be infused via the same apparatus as blood or plasma, because the peptide linkages are rapidly inactivated by oxytocin-inactivating enzymes. Oxytocin is incompatible with solutions containing sodium metabisulphite as a stabiliser.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Before opening: </em></p><p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package.</p><p>&nbsp;</p><p><em>After dilution: </em></p><p>The diluted solutions should be used immediately.<sup> &nbsp;</sup></p><p>If your doctor decides to stop your treatment, return any unused medicine to the pharmacist. Only keep it if your doctor tells you to.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1 ml clear glass type I ampoules.</p><p>&nbsp;</p><p>Pack size: 6 Ampoules (1 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Gynocin 5 IU/0.5 ml and 10 IU/ml Concentrate for Solution for Injection/Infusion has been shown to be compatible when diluted with 500 ml of the following intravenous infusion fluids to an approximate concentration of 0.01 IU/ml or 0.02 IU/ml; respectively:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp; 0.9% Sodium chloride solution</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp; 5% Dextrose solution</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp; Ringer lactate solution</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                31 August 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>